SynthesisEuropean journal of clinical investigation2025
Torque teno virus as a marker of immune status in immunocompromised patients: A systematic review.
Synthesis in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Torque Teno Virus (TTV) Plasma Load and Immune Reconstitution Post-Transplantation in Patients with Lymphoproliferative Disorders: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
- Torque teno virus as a marker of immune status in immunocompromised patients: A systematic review.European journal of clinical investigation · 2025Pooled it
- Association of torque teno virus in periodontitis: a systematic review, meta-analysis, and trial sequential analysis.Frontiers in oral health · 2025Pooled it
- Reproducibility and Potential for Input Reduction for Torque Teno Virus DNA Quantification in Rheumatoid Arthritis.Medical sciences (Basel, Switzerland) · 2026Article
- Torque teno virus in the lower respiratory tract: association with immunosuppression but not mortality in severe pneumonia-a multicenter retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Torque Teno Virus Dynamics in Plasma and BAL of COVID-19 ARDS Patients With and Without ECMO.Journal of medical virology · 2026Article
- Torque Teno Virus (TTV) Plasma Load and Immune Reconstitution in People Living with HIV: A Systematic Review.Microorganisms · 2026Review
- TTV virome marks immune exhaustion, α7nAChR alteration, and mortality in elderly patients with severe COPD.GeroScience · 2026Article
- TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses.Vaccines · 2026Article
- Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTorque teno virus (TTV) is not known to cause disease in humans; however, chronic inflammatory conditions and immunosuppression states can favour TTV replication. This study aimed to verify the effectiveness of TTV as an immune biomarker.
methodsThe protocol of this review was registered in PROSPERO (CRD42022331049) and performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
resultsThirty-three articles were selected and different groups of patients were assessed. In the solid organ and hematopoietic stem cell transplant groups, most studies reported that TTV viral load (VL) was highly detectable after transplantation and compared to controls, but the association with immune parameters showed conflicting results. In melanoma patients, no statistical difference in TTV VL was identified between susceptible and treatment-resistant patients. In lung cancer patients, viral load increases significantly with disease progression but decreases after chemotherapy. HIV-positive patients showed a higher VL than controls, but an inverse correlation with CD4+ was observed in half of the studies. Although 57.14% of all studies presented a low risk of bias, significant differences were observed between studies, particularly in the choice of the analyzed outcome, the parameter used to evaluate the patient's immune status, the presence of a control group, and the sample collection time points.
conclusionsAlthough TTV seems to have the potential to be a promising biomarker of immunosuppression, further high-quality prospective clinical studies are still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.